| systematic review | Q1504425 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Allan Wailoo | Q90186791 |
| Abdullah Pandor | Q37370200 | ||
| Munira Essat | Q38639882 | ||
| John Rathbone | Q63371992 | ||
| P2093 | author name string | Ruth Wong | |
| Edith Poku | |||
| Emma Everson-Hock | |||
| P2860 | cites work | Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results | Q83471053 |
| One-year outcomes of less frequent bevacizumab in age-related macular degeneration | Q83492444 | ||
| Comparing ranibizumab with bevacizumab | Q83534726 | ||
| Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study | Q83677110 | ||
| Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization | Q84206800 | ||
| Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema | Q84586581 | ||
| Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema | Q84708284 | ||
| Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial | Q84716253 | ||
| [Six cases of sterile endophthalmitis developed consecutively after intravitreal injection of bevacizumab] | Q84867441 | ||
| Comparing treatment of neovascular age-related macular degeneration with sequential intravitreal Avastin and Macugen versus intravitreal mono-therapy--a pilot study | Q84995527 | ||
| Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial | Q85091675 | ||
| Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia | Q95818525 | ||
| Leading causes of certification for blindness and partial sight in England & Wales | Q21257225 | ||
| How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis | Q24273261 | ||
| Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results | Q24633874 | ||
| Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness | Q24674358 | ||
| The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions | Q27860564 | ||
| Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial | Q28294837 | ||
| Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab | Q33259913 | ||
| A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema | Q33294185 | ||
| One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion | Q33359405 | ||
| Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration | Q33378209 | ||
| Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. | Q33383060 | ||
| Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion | Q33403486 | ||
| A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. | Q33563565 | ||
| Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents | Q33655007 | ||
| Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review | Q33726705 | ||
| A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections | Q33982800 | ||
| Bevacizumab therapy for macular edema in central retinal vein occlusion: Long-term results | Q33999888 | ||
| A prospective, randomized comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab (avastin) in diffuse diabetic macular edema | Q34107543 | ||
| Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. | Q34627103 | ||
| Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema | Q35009731 | ||
| A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications. | Q35226722 | ||
| Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. | Q36075546 | ||
| Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration | Q36983512 | ||
| Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection | Q37132681 | ||
| Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. | Q37226286 | ||
| Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment | Q37364125 | ||
| Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion | Q37463972 | ||
| Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy | Q37637882 | ||
| Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation | Q37645651 | ||
| Subconjunctival reflux and need for paracentesis after intravitreal injection of 0.1 ml bevacizumab: comparison between 27-gauge and 30-gauge needle | Q37781722 | ||
| Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia | Q37823154 | ||
| Effect of reflux of drug during intravitreal anti-VEGF therapies on foveal thickness. | Q37862253 | ||
| Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial | Q38009430 | ||
| Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections | Q38017771 | ||
| Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema | Q42857767 | ||
| A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion | Q42881016 | ||
| Treatment of branch retinal vein occlusion induced macular edema in treatment-naïve cases with a single intravitreal triamcinolone or bevacizumab injection | Q42922182 | ||
| Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study | Q43009206 | ||
| Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study | Q43031322 | ||
| Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study | Q43076806 | ||
| Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial | Q43155615 | ||
| Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results | Q43222037 | ||
| Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study | Q43236529 | ||
| Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration | Q44249268 | ||
| Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. | Q44299836 | ||
| Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents | Q45233247 | ||
| Bilateral simultaneous intravitreal injections in the office setting | Q45761367 | ||
| Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration. | Q45919219 | ||
| Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization. | Q45931378 | ||
| Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). | Q45997338 | ||
| The treatment of choroidal neovascularizations in age-related macular degeneration using either Avastin or Lucentis | Q46041334 | ||
| Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. | Q46046331 | ||
| Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection | Q46121306 | ||
| Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments | Q46131421 | ||
| Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. | Q46386792 | ||
| Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. | Q46679896 | ||
| Short-term complications of intravitreal injections of triamcinolone and bevacizumab | Q46739563 | ||
| Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study | Q46796763 | ||
| Complications in patients after intravitreal injection of bevacizumab. | Q46889796 | ||
| Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. | Q46960496 | ||
| Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial | Q46965253 | ||
| Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results | Q46985099 | ||
| Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique | Q48228197 | ||
| Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization. | Q50498426 | ||
| Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial. | Q50510449 | ||
| Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. | Q50677029 | ||
| Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma. | Q50990756 | ||
| Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. | Q51171123 | ||
| Short-term intraocular pressure changes after intravitreal injection of bevacizumab. | Q51727373 | ||
| Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. | Q54674875 | ||
| Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study | Q57136732 | ||
| Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES) | Q60197408 | ||
| Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study | Q79151606 | ||
| Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration | Q79366369 | ||
| Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration | Q79421339 | ||
| Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration | Q80420502 | ||
| Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment | Q80692437 | ||
| Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab | Q82129823 | ||
| Multifocal electrophysiologic findings after intravitreal bevacizumab (avastin) treatment | Q82619812 | ||
| Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections | Q82845669 | ||
| The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension | Q82949549 | ||
| Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales' disease | Q82957366 | ||
| Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema | Q83205520 | ||
| Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion | Q83366673 | ||
| Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study | Q83387172 | ||
| Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1) | Q83451435 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | globulins | Q321710 |
| bevacizumab | Q413299 | ||
| monoclonal antibody | Q422248 | ||
| blood proteins | Q425056 | ||
| systematic review | Q1504425 | ||
| eye disease | Q3041498 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e005244 | |
| P577 | publication date | 2014-07-17 | |
| P1433 | published in | BMJ Open | Q17003470 |
| P1476 | title | The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review | |
| P478 | volume | 4 |
| Q36683809 | A Drug Delivery System for Administration of Anti-TNF-α Antibody |
| Q55412994 | Bevacizumab Diminishes Inflammation in an Acute Endotoxin-Induced Uveitis Model. |
| Q53066865 | Choroidal melanoma treated with stereotactic fractionated radiotherapy and prophylactic intravitreal bevacizumab: The Dunedin Hospital experience. |
| Q39865676 | Intravitreal administration of bevacizumab: pros and cons |
| Q93118283 | Novel Triamcinolone Acetonide-Loaded Liposomal Topical Formulation Improves Contrast Sensitivity Outcome After Femtosecond Laser-Assisted Cataract Surgery |
| Q64094064 | Novel Triamcinolone Acetonide-Loaded Liposomes Topical Formulation for the Treatment of Cystoid Macular Edema After Cataract Surgery: A Pilot Study |
| Q58804239 | Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study |
| Q92982528 | Severe epistaxis related to intravitreal bevacizumab |
| Q54145708 | Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema. |
| Q42578478 | The short-needle intravitreal injection technique |
Search more.